These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36925069)

  • 1. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
    Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
    Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
    Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
    Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.
    Fernandez AI; Robbins CJ; Gaule P; Agostini-Vulaj D; Anders RA; Bellizzi AM; Chen W; Chen ZE; Gopal P; Zhao L; Lisovsky M; Liu X; Shia J; Wang H; Yang Z; McCann L; Chan YG; Weidler J; Bates M; Zhang X; Rimm DL
    Mod Pathol; 2023 May; 36(5):100128. PubMed ID: 36889057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
    Nuti S; Zhang Y; Zerrouki N; Roach C; Bänfer G; Kumar GL; Manna E; Diezko R; Kersch K; Rüschoff J; Jasani B
    Histopathology; 2022 Dec; 81(6):732-741. PubMed ID: 35993150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
    Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
    Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
    Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
    Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
    Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
    Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
    Heo YJ; Kim B; Kim H; Kim S; Jang MS; Kim KM
    Pathol Res Pract; 2021 Feb; 218():153338. PubMed ID: 33440275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
    Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
    Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
    Ahn S; Kim KM
    Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
    Kulangara K; Zhang N; Corigliano E; Guerrero L; Waldroup S; Jaiswal D; Ms MJ; Shah S; Hanks D; Wang J; Lunceford J; Savage MJ; Juco J; Emancipator K
    Arch Pathol Lab Med; 2019 Mar; 143(3):330-337. PubMed ID: 30028179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
    Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
    Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
    Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
    Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
    Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.